There is a high unmet need for durable therapeutic options for cancer patients, as current drugs often lose their effectiveness over time. Drug resistance therefore remains a major limiting factor to patient survival.
TOLREMO’s platform has the potential to generate a new wave of novel resistance-breaking therapies by targeting the resistance-causing molecular mechanisms right from the start. By combining TOLRMEO’s add-on compounds with existing cancer drugs and a proprietary screening platform, the company aims to ensure that the right patient is treated with the right drug at the right time.